Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Current Deferred Revenue (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Current Deferred Revenue for 16 consecutive years, with $189000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 77.74% to $189000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $189000.0 through Dec 2025, down 77.74% year-over-year, with the annual reading at $189000.0 for FY2025, 77.74% down from the prior year.
  • Current Deferred Revenue hit $189000.0 in Q4 2025 for Guided Therapeutics, down from $689318.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $278.0 million in Q3 2021 to a low of $62000.0 in Q1 2021.
  • Historically, Current Deferred Revenue has averaged $14.4 million across 5 years, with a median of $511050.5 in 2022.
  • Biggest five-year swings in Current Deferred Revenue: soared 661804.76% in 2021 and later tumbled 99.82% in 2022.
  • Year by year, Current Deferred Revenue stood at $337315.0 in 2021, then soared by 50.93% to $509101.0 in 2022, then decreased by 16.67% to $424225.0 in 2023, then soared by 100.11% to $848917.0 in 2024, then plummeted by 77.74% to $189000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for GTHP at $189000.0 in Q4 2025, $689318.0 in Q3 2025, and $679318.0 in Q2 2025.